JUPITER, Fla. — March 4, 2026 — Leads & Copy — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced today that its senior management team will participate in upcoming investor conferences.
Ligand management is scheduled to host one-on-one meetings with investors during these conferences. Investors interested in arranging one-on-one meetings should contact their Leerink, ROTH, or NAHC representative.
The conferences include:
Leerink Partners Global Healthcare Conference (Miami): Management will participate in one-on-one meetings March 11, 2026.
38th Annual ROTH Conference (Dana Point, Calif.): Management will present at 1:00 p.m. PT on March 23, 2026.
Nordic-American Healthcare Conference 2026 (New York): Management will present at 3:45 p.m. ET on March 25, 2026.
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand provides financing and licenses technologies.
The company’s business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams supported by an efficient and low corporate cost structure. The goal is to offer investors an opportunity to participate in the biotech industry in a profitable and diversified manner.
Ligand’s business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products, and licensing its technology to help partners discover and develop medicines. The company partners with other pharmaceutical companies to attempt to leverage late-stage development, regulatory management and commercialization in order to generate revenue.
Ligand operates two infrastructure-light royalty generating technology IP platform technologies. The Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications.
Ligand has established multiple alliances, licenses and other business relationships with pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International.
The company uses its investor relations website and X as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD. Investors should monitor the website and X account, in addition to following press releases, SEC filings, public conference calls and webcasts.
Source: Ligand Pharmaceuticals
